ergotamine and mdl 100907

ergotamine has been researched along with mdl 100907 in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benwell, K; Bickerdike, M; Kennett, G; Knight, AR; Misra, A; Quirk, K; Revell, D1
Aiken, GE; Brown, KR; Bush, LP; Johnson, JM; Klotz, JL; Strickland, JR1
Bjørn-Yoshimoto, WE; Che, T; Cheng, J; Ding, K; Gloriam, DE; Han, GW; Hanson, MA; Harpsøe, K; Huang, XP; Jensen, AA; Katritch, V; Lansu, K; Liu, ZJ; McCorvy, JD; Nikolajsen, LF; Peng, Y; Popov, P; Pu, M; Qu, L; Roth, BL; Shen, L; Stevens, RC; Wacker, D; Wu, Y; Yuan, S; Zhao, S1

Other Studies

3 other study(ies) available for ergotamine and mdl 100907

ArticleYear
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
    Naunyn-Schmiedeberg's archives of pharmacology, 2004, Volume: 370, Issue:2

    Topics: Binding Sites; Binding, Competitive; Cell Line; Humans; Radioligand Assay; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2B; Receptor, Serotonin, 5-HT2C; Recombinant Proteins; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Serotonin Receptor Agonists

2004
Antagonism of lateral saphenous vein serotonin receptors from steers grazing endophyte-free, wild-type, or novel endophyte-infected tall fescue.
    Journal of animal science, 2013, Volume: 91, Issue:9

    Topics: Animal Feed; Animals; Cattle; Diet; Endophytes; Ergolines; Ergot Alkaloids; Ergotamine; Ergotamines; Festuca; Lolium; Male; Neotyphodium; Random Allocation; Saphenous Vein; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists

2013
5-HT
    Cell, 2018, 02-08, Volume: 172, Issue:4

    Topics: Ergotamine; HEK293 Cells; Humans; Obesity; Protein Domains; Receptor, Serotonin, 5-HT2C; Ritanserin; Schizophrenia; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Structure-Activity Relationship; Substance-Related Disorders

2018